Menu
Recruiting NCT06378619

Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach

Observational Tremor Essential Tremor Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tapping Test, Archimedes Spiral.
Who it may be relevant to
Registry conditions: Tremor, Essential Tremor, Parkinson Disease. Basic parameters: 45 years — 79 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Machine Learning Analysis Of The Tapping Test And The Archimedean Spiral For The Differential Diagnosis Of Essential Tremor And Parkinson's Disease.

Overview

In clinical practice, it is sometimes difficult to establish whether a patient's tremor is due to Parkinson's disease or essential tremor. The distinction is crucial as the health implications differ significantly between the two conditions. Therefore, the present study aims to develop a diagnostic method based on machine learning techniques to help differentiate whether a patient's tremor is due to one condition or the other. To achieve this, 110 patients with tremor, correctly diagnosed with either Parkinson's disease or essential tremor, will participate. They will undergo two diagnostic tests (tapping test and Archimedean spiral) to capture data that can be processed using machine learning techniques.

Interventions

  • Diagnostic test Tapping Test
    For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
  • Diagnostic test Archimedes Spiral
    For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.

Primary outcome measures

  • Sensitivity [Time frame: through study completion, an average of 1 year]
  • Specificity [Time frame: through study completion, an average of 1 year]
Secondary outcome measures (1)
  • Reliability [Time frame: through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • Possibility to collaborate in the necessary evaluations.
  • Follow-up in the specialized consultation of Movement Disorders at the Neurology Service of Hospital Sant Camil-Consorci Sanitari Alt Penedes i Garraf.
  • Legal capacity to provide informed consent.
  • Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.
  • Participant with criteria from Group 1 or 2:

Group 1:

  • Confirmed diagnosis of tremor due to Parkinson's disease, clinically established, based on the diagnostic criteria of the Movement Disorders Society, and additionally:
  • Tremor associated with bradykinesia of any duration.
  • Confirmatory clinical diagnosis of tremor due to Parkinson's disease (stages 1 to 2 of Hoehn and Yahr) by the neurologist responsible for the participant's follow-up.

Group 2:

  • Confirmed diagnosis of essential tremor, based on the criteria of the Movement Disorders Society, and additionally:
  • Positional tremor plus kinetic and/or resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis.
  • Absence of bradykinesia.

Exclusion criteria

  • Patients undergoing treatment with antipsychotics or antidepressants.
  • Patients with Parkinson's disease and dyskinesias.
  • Patients undergoing treatment with dopaminergic agonists or primidone.
  • Tremor of such severity that it prevents continuous tracing, at the investigator's discretion.
  • Cognitive or affective pathology that limits the ability to collaborate with the study procedures.
  • Participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study.
  • Participants diagnosed with any of the following conditions:

Alcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. Peripheral neuropathy of any cause. Dystonias. Previous stroke.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-crossover

Study locations

Spain · 1 center
  • Hospital Sant Camil-Consorci Sanitari Alt'Pènedes i Garraf — Barcelona

Identifiers

NCT: NCT06378619 · CSAPG-50

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗